- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Evommune beschafft 125 Millionen US-Dollar über Privatplatzierung für Forschung und Entwicklung | 1 | Investing.com Deutsch | ||
| Fr | Evommune raises $125 million in private placement to fund R&D | 1 | Investing.com | ||
| Fr | Evommune raises $125M privately | 1 | Seeking Alpha | ||
| Do | Evommune Stock Cools Off After Big Rally On Successful Eczema Trial | 1 | Benzinga.com | ||
| Mi | Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill | 7 | BioPharma Dive | ||
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| Di | Evommune Starts Making Case to Challenge Dominance of Sanofi's Dupixent in Atopic Dermatitis | 26 | MedCity News | ||
| Di | Evommune: Evercore ISI hebt Kursziel nach positiven Studiendaten auf 55 US-Dollar an | 15 | Investing.com Deutsch | ||
| Di | Evommune stock price target raised to $55 by Evercore ISI on positive trial data | 1 | Investing.com | ||
| Di | Evommune's Stock Surges On Strong Results For New Eczema Drug | 1 | Benzinga.com | ||
| Di | Evommune's Dupixent-like phase 2 eczema data drive 75% stock rally | 3 | FierceBiotech | ||
| Di | Evommune surges on mid-stage trial win for eczema therapy | 1 | Seeking Alpha | ||
| Di | Positive Studiendaten zu Ekzem-Medikament beflügeln Evommune-Aktie | 1 | Investing.com Deutsch | ||
| Di | Evommune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Evommune's atopic dermatitis drug meets primary endpoint in phase 2a trial | 1 | Investing.com | ||
| 07.01. | Raymond James startet Coverage für Evommune mit "Strong Buy" und Kursziel von 40 $ | 3 | Investing.com Deutsch | ||
| 07.01. | Raymond James initiates Evommune stock with Strong Buy rating, $40 target | 3 | Investing.com | ||
| 06.01. | Evommune: H.C. Wainwright startet Coverage mit "Buy"-Rating wegen Urtikaria-Potenzial | 15 | Investing.com Deutsch | ||
| 11.12.25 | Evommune, Inc. GAAP EPS of -$8.07, revenue of $10M | 1 | Seeking Alpha | ||
| 11.12.25 | Evommune, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.12.25 | Evommune, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DISC MEDICINE | 56,12 | -21,67 % | Disc Medicine Inc: Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP | FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use... ► Artikel lesen | |
| ARCELLX | 68,50 | -0,22 % | Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study | ||
| AVIDITY BIOSCIENCES | 72,88 | -0,05 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| QIAGEN | 42,905 | +0,13 % | ANALYSE-FLASH: Berenberg hebt Ziel für Qiagen auf 50 Euro - 'Buy' | HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der Diagnostikspezialist... ► Artikel lesen | |
| UPSTREAM BIO | 8,740 | -31,72 % | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | - Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing - - Verekitug also delivered... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,78 | -3,91 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| ZENAS BIOPHARMA | 26,520 | +1,57 % | Zenas BioPharma's MS drug shows 95% reduction in brain lesions | ||
| APOGEE THERAPEUTICS | 67,74 | -2,27 % | Here is Why Apogee Therapeutics (APGE) Appears Attractive | ||
| PRAXIS PRECISION MEDICINES | 317,31 | -4,69 % | Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) | ||
| RECURSION PHARMACEUTICALS | 3,495 | -2,37 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,930 | +3,71 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| ERASCA | 12,020 | -2,36 % | Stifel bestätigt Kaufempfehlung für Erasca mit Kursziel von 10 US-Dollar | ||
| MINERALYS THERAPEUTICS | 27,600 | -0,93 % | Mineralys Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TANGO THERAPEUTICS | 12,900 | +1,82 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| IMMUNOME | 22,160 | -1,25 % | H.C. Wainwright initiates coverage on Immunome stock with Buy rating |
EVOMMUNE INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +14,09 % bei einem Aktienkurs von 31,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.